Drug-metabolizing cytochrome P450 enzymes have multifarious influences on treatment outcomes

Y Song, C Li, G Liu, R Liu, Y Chen, W Li, Z Cao… - Clinical …, 2021 - Springer
Drug metabolism is a critical process for the removal of unwanted substances from the body.
In humans, approximately 80% of oxidative metabolism and almost 50% of the overall …

Cytochrome P450 expression and regulation in the brain

W Kuban, WA Daniel - Drug Metabolism Reviews, 2021 - Taylor & Francis
The regulation of brain cytochrome P450 enzymes (CYPs) is different compared with
respective hepatic enzymes. This may result from anatomical bases and physiological …

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

I Waku, MS Magalhaes, CO Alves… - European Journal of …, 2021 - Wiley Online Library
Several useful animal models for parkinsonism have been developed so far. Haloperidol‐
induced catalepsy is often used as a rodent model for the study of motor impairments …

CYP-mediated drug metabolism in the brain impacts drug response

DM McMillan, RF Tyndale - Pharmacology & therapeutics, 2018 - Elsevier
The functional role of cytochrome P450 (CYP) enzymes in the brain is an exciting and
evolving field of research. CYPs are present and active in the brain, with heterogeneous …

The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug-drug interactions

WA Daniel, E Bromek, PJ Danek, A Haduch - Biochemical Pharmacology, 2022 - Elsevier
Cytochrome P450 (CYP) plays an important role in psychopharmacology. While liver CYP
enzymes are responsible for the biotransformation of psychotropic drugs, brain CYP …

Tardive dyskinesia: Who gets it and why

K Frei - Parkinsonism & Related Disorders, 2019 - Elsevier
Tardive dyskinesia (TD) is a potentially permanent movement disorder resulting from chronic
use of dopamine receptor blocking agents (DRBA). Identified risk factors include the type of …

Genetics of tardive dyskinesia: promising leads and ways forward

CC Zai, MS Maes, AK Tiwari, GC Zai… - Journal of the …, 2018 - Elsevier
Tardive dyskinesia (TD) is a potentially irreversible and often debilitating movement disorder
secondary to chronic use of dopamine receptor blocking medications. Genetic factors have …

[HTML][HTML] Alterations of cytochrome P450s and UDP-glucuronosyltransferases in brain under diseases and their clinical significances

Y Sheng, H Yang, T Wu, L Zhu, L Liu… - Frontiers in …, 2021 - frontiersin.org
Cytochrome P450s (CYPs) and UDP-glucuronosyltransferases (UGTs) are both greatly
important metabolic enzymes in various tissues, including brain. Although expressions of …

[HTML][HTML] Genetic factors associated with tardive dyskinesia: from pre-clinical models to clinical studies

EE Tsermpini, S Redenšek, V Dolžan - Frontiers in pharmacology, 2022 - frontiersin.org
Tardive dyskinesia is a severe motor adverse event of antipsychotic medication,
characterized by involuntary athetoid movements of the trunk, limbs, and/or orofacial areas …

Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia

N Arguelles, J Richards, AA El-Sherbeni… - Biochemical …, 2022 - Elsevier
Opioids, and numerous centrally active drugs, are metabolized by cytochrome P450 2D
(CYP2D). There are sex and estrous cycle differences in brain oxycodone analgesia. Here …